单克隆抗体靶向治疗肿瘤策略及安全性

Strategy and safety of monoclonal antibody targeted therapy for tumor

随着单克隆抗体(McAb)制备技术日臻成熟,其在肿瘤靶向治疗中得到了广泛应用。McAb靶向治疗肿瘤的策略分为:(1)以肿瘤细胞表面抗原或促肿瘤形成细胞因子及其受体为靶点,通过抗体发挥生物学活性而产生抗肿瘤效应;(2)免疫细胞治疗,主要包括肿瘤特异性T淋巴细胞活化及抑制解除。McAb靶向治疗肿瘤中,由于缺乏肿瘤特异性抗原及对免疫应答的非生理性调节,这种治疗手段也会带来如脱靶效应、细胞因子风暴、变态反应等一系列免疫相关不良事件,应当引起关注。

With the development of the monoclonal antibody(McAb)preparation technology,its targeted tumor therapy has become widely used.McAb targeted tumor treatment strategies are divided into:(1)Tumor cell surface antigens or tumor-promoting cytokines and their receptors are used as targets to produce anti-tumor effects through the biological activity of antibodies;(2)Immune cell therapy.It mainly includes the activation and suppression of tumor-specific T lymphocytes.In McAb targeted treatment of tumors,due to the lack of tumor-specific antigens and non-physiological regulation to immune response,this treatment method will also bring a series of immune-related adverse events such as off-target effect,cytokine storms,and allergic reactions.These events should be concerned.